“…First, many virions are currently used to evaluate antiviral effects, and there is no consensus on their selection to data. The representative coronaviruses used in the literature were SARS-CoV-2, bovine coronavirus, MHV-A59, , HCoV-229E, and HCoV-OC43. , Currently, bacteriophages are the common alternative to the high-risk viruses used in a biosafety level 3 facility, such as T4, T7, Φ6, p22, and MS2. ,,− Besides, other virus alternatives, such as HAdV5, HSV-1, and H1N1, were also reported frequently. ,, Moreover, even bacteria such as Pseudomonas aeruginosa have served as viral models based on the claim that their binding site residues are highly similar to that of SARS-CoV-2 . This situation inevitably leads to difficulty in comparing the antiviral activities reported in different reports, which was pointed out by Camero as well that the resistance behaviors of a virus family against chemical and physical reagents are significantly characteristic and quite different than other families.…”